Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 9:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 2,082 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Vision Disorder Clear all
Not listed Not applicable Interventional Accepts healthy volunteers

Light-deprivation Utilized to Mitigate Amblyopia

NCT02685423
View directory record Official record
Conditions
Amblyopia
Interventions
Binocular deprivation 10 days, Vision training
Behavioral
Lead sponsor
State University of New York College of Optometry
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 29, 2019 · Synced Oct 28, 2026, 9:55 PM EDT
Recruiting Phase 3 Interventional

OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity

NCT07140783
View directory record Official record
Conditions
Vision Loss Night, Vision Disorders
Interventions
0.75% Phentolamine Ophthalmic Solution, Placebo
Drug
Lead sponsor
Opus Genetics, Inc
Industry
Eligibility
18 Years and older
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
20
States / cities
Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 28, 2026, 9:55 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

The Effects of Concussion on Gait and Posture in Individuals With Peripheral Vision Loss

NCT05948501
View directory record Official record
Conditions
Concussion, Eye
Interventions
Not listed
Lead sponsor
Gaylord Hospital, Inc
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
New Haven, Connecticut • Wallingford, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Oct 28, 2026, 9:55 PM EDT
Terminated No phase listed Observational

Imaging Lens Deposits in Exfoliation Syndrome

NCT02042703
View directory record Official record
Conditions
Exfoliation Syndrome, Primary Open Angle Glaucoma, Cataracts
Interventions
anterior segment OCT
Device
Lead sponsor
Duke University
Other
Eligibility
40 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 21, 2015 · Synced Oct 28, 2026, 9:55 PM EDT
Recruiting Phase 3 Interventional

Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma

NCT07804186
View directory record Official record
Conditions
Uveal Melanoma
Interventions
Darovasertib, Crizotinib (Xalkori)
Drug
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
11
States / cities
Scottsdale, Arizona • Los Angeles, California • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 28, 2026, 9:55 PM EDT
Recruiting Phase 3 Interventional

A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome

NCT07710196
View directory record Official record
Conditions
Retinitis Pigmentosa (RP), Usher Syndrome
Interventions
Placebo, NPI-001
Drug
Lead sponsor
Nacuity Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 28, 2026, 9:55 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

NCT03657797
View directory record Official record
Conditions
Glaucoma, Open-Angle, Hypertension, Ocular
Interventions
NCX 470, Latanoprost 0.005%
Drug
Lead sponsor
Nicox Ophthalmics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 28, 2026, 9:55 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Validity of at Home Visual Acuity Measurements for Telemedicine During Corona Virus (COVID-19) Pandemic

NCT04391166
View directory record Official record
Conditions
Visual Impairment
Interventions
Non invasive visual acuity testing
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Oct 28, 2026, 9:55 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)

NCT05335122
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
OTX-TIC low dose Travoprost Intracameral Implant, OTX-TIC high dose Travoprost Intracameral Implant, Durysta, Bimatoprost Intracameral Implant 10 µg
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
30
States / cities
Dothan, Alabama • Huntington Beach, California • Irvine, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 28, 2026, 9:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluating and Improving Functional Driving Vision of Patients With Astigmatism: Phase 3

NCT02950545
View directory record Official record
Conditions
Astigmatism
Interventions
Placebo Lenses, Spherical Lenses, Toric Lenses
Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 39 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Oct 28, 2026, 9:55 PM EDT
Not listed Not applicable Interventional

Stem Cell Ophthalmology Treatment Study

NCT01920867
View directory record Official record
Conditions
Retinal Disease, Macular Degeneration, Hereditary Retinal Dystrophy, Optic Nerve Disease, Glaucoma
Interventions
RB (Retrobulbar), ST (Subtenon), IV (Intravenous), IVIT (Intravitreal), IO (Intraocular)
Procedure
Lead sponsor
MD Stem Cells
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Westport, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Oct 28, 2026, 9:55 PM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 Mutation

NCT02652767
View directory record Official record
Conditions
Optic, Atrophy, Hereditary, Leber
Interventions
GS010, Sham Intravitreal Injection
Biological · Device
Lead sponsor
GenSight Biologics
Industry
Eligibility
15 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Los Angeles, California • Atlanta, Georgia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 28, 2026, 9:55 PM EDT
Terminated Phase 2 Interventional

Effects Of GW679769 On Bladder Nerve Function And Symptoms Of Overactive Bladder In Spinal Cord Injury Patients

NCT00332319
View directory record Official record
Conditions
Incontinence, Urinary and Urinary Bladder, Overactive, Overactive Bladder
Interventions
GW679769
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
3
States / cities
Long Beach, California • Cleveland, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 17, 2015 · Synced Oct 28, 2026, 9:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects

NCT02103894
View directory record Official record
Conditions
Alzheimer's Disease (AD), Parkinson's Disease (PD), Chronic Traumatic Encephalopathy (CTE), Progressive Supranuclear Palsy (PSP), Frontal Temporal Dementia (FTD), Pick's Disease, Tauopathies
Interventions
[18F]T807 ([18F]MNI-777)
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 28, 2026, 9:55 PM EDT
Recruiting Not applicable Interventional

Light Exposure, Migraine Outcomes, and Sleep Quality

NCT07476053
View directory record Official record
Conditions
Migraine Headache, Sleep, Photophobia
Interventions
Ambient Lighting Condition
Other
Lead sponsor
Arizona State University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 28, 2026, 9:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Autoimmune Dysregulation in Pigmentary Glaucoma

NCT00280345
View directory record Official record
Conditions
Pigmentary Glaucoma, Primary Open Angle Glaucoma, Cataract
Interventions
Trabeculectomy, Trabeculectomy and cataract surgery, Cataract surgery
Procedure
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 85 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Oct 28, 2026, 9:55 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Treating Amblyopia With CureSight

NCT06165705
View directory record Official record
Conditions
Amblyopia
Interventions
CureSight
Device
Lead sponsor
Alaska Blind Child Discovery
Other
Eligibility
2 Years to 20 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Anchorage, Alaska
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Oct 28, 2026, 9:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study

NCT02390245
View directory record Official record
Conditions
Glaucoma, Glaucoma Suspect, Diabetic Retinopathy, Ocular Hypertension, Cataract, Branch Retinal Vein Occlusion, Branch Retinal Arterial Occlusion, Central Retinal Vein Occlusion, Central Retinal Artery Occlusion, Epi-retinal Membrane, Macular Degeneration, Drusen, Loss of Vision
Interventions
Free Eye Screenings, Enhanced Intervention, Usual Care
Other
Lead sponsor
Wills Eye
Other
Eligibility
40 Years and older
Enrollment
906 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Oct 28, 2026, 9:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pilot Study to Investigate the Feasibility, Reliability and Efficacy of Utilizing OCT to Automate PROSE Fitting

NCT04649177
View directory record Official record
Conditions
Keratoconus, Ocular Surface Disease, Pellucid Marginal Corneal Degeneration, Ectasia, Corneal Trauma, Corneal Scar, Dry Eye Syndromes, Keratoconjunctivitis Sicca, Sjogren's Syndrome
Interventions
Ocular surface optical coherence tomography
Device
Lead sponsor
Boston Sight
Other
Eligibility
21 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 27, 2023 · Synced Oct 28, 2026, 9:55 PM EDT
Completed Early Phase 1 Interventional

Does Oral Acetaminophen Lower Intraocular Pressure?

NCT02366065
View directory record Official record
Conditions
Glaucoma
Interventions
Acetaminophen
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 7, 2016 · Synced Oct 28, 2026, 9:55 PM EDT
Terminated Not applicable Interventional Results available

Comparing Acular LS and Pred Forte in Reducing Post-selective Laser Trabeculoplasty Anterior Chamber Flare and Cells

NCT00478036
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Acular LS, Pred Forte, Refresh Tears
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 7, 2016 · Synced Oct 28, 2026, 9:55 PM EDT
Completed Phase 2 Interventional Results available

SYL040012, Treatment for Open Angle Glaucoma

NCT02250612
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
1 drop of 0.375% SYL040012 (bamosiran), 1 drop of 0.750% SYL040012 (bamosiran), 1 drop of 1.125% SYL040012 (bamosiran), 1 drop of 1.5% SYL040012 (bamosiran), 1 drop of 0.5 % timolol maleate
Drug
Lead sponsor
Sylentis, S.A.
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Artesia, California • Petaluma, California • Morrow, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Oct 28, 2026, 9:55 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity

NCT00634972
View directory record Official record
Conditions
Retinopathy of Prematurity, Retinal Detachment, Blindness
Interventions
ACULAR, REFRESH TEARS, placebo
Drug
Lead sponsor
University of South Alabama
Other
Eligibility
10 Days to 15 Days
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 28, 2026, 9:55 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Study to See if an iPhone Weight Management App Can Help Promote Weight Loss in Adolescents and Young Adults After a Stem Cell Transplant

NCT04453072
View directory record Official record
Conditions
Obesity, Malignant Neoplasm
Interventions
Interview, Media Intervention, Questionnaire Administration, Scale Device, Telephone-Based Intervention, Text Message
Other · Behavioral
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
13 Years to 30 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 28, 2026, 9:55 PM EDT